Evaxion Shares Latest EVX-01 Phase 2 Clinical Data In Webinar With Key Opinion Leader Adnan Khattak

Benzinga ·  Nov 6, 2023 10:13
  • EVX-01 is Evaxion's lead clinical asset based upon its AI-Immunology platform and has recently published a phase 2 clinical update confirming former phase 1 results

  • Principal investigator Professor Adnan Khattak will walk us through this study's encouraging results and explain its potential for revolutionizing cancer treatment

COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in the development of AI-Immunology powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and study's Principal Investigator (PI), Professor Adnan Khattak. The webinar will take place...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment